Biological Dynamics Announces $26.8M Series C Financing
/Biological Dynamics, Inc., a molecular diagnostics company, announced today that it has completed a $26.8M round of financing.
Read MoreBiological Dynamics, Inc., a molecular diagnostics company, announced today that it has completed a $26.8M round of financing.
Read MoreBiological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.